OPHIREX, INC.

ACTIVE

5643 Paradise Dr Ste 2, 加利福尼亚州马林县, California, United Stateswww.ophirex.comHolding11–50 employeesEstablished: 2015-01-01

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2015

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

100.0%

Trial Status Distribution

Completed

60.0%

Not yet recruiting

20.0%

Terminated

20.0%

Clinical Trials

Trials sponsored by this organization (5)

A study of Varespladib, a Snake Venom Toxin Inhibitor, for Snakebite.

Phase 2

Completed

interventional

Nov 2023140 participants

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

Phase 2

Completed

interventional

May 2023140 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations

OPHIREX, INC.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (5)

A study of Varespladib, a Snake Venom Toxin Inhibitor, for Snakebite.

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite

Study of Varespladib in Patients Hospitalized With Severe COVID-19

A study of Varespladib, a Snake Venom Toxin Inhibitor, for Snakebite.

Approvals

News